Gastroparesis Clinical Trials

Find Gastroparesis Clinical Trials Near You

Modulation of Gastric Sensitivity and Accommodation by Vagal Nerve Stimulation

Who is this study for? Patients with Dyspepsia, Gastroparesis
What treatments are being studied? taVNS
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in functional dyspepsia and gastroparesis patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:

• Volunteers, female and male, between 18 and 65 years of age.

• For healthy volunteers, ability to undergo MRI for up to 2 hours.

• For Functional Dyspeptic patients, diagnosis according to the Rome III criteria for both PDS and EPS subtypes.

• For Gastroparesis patients, diagnosis will include the following criteria:

‣ symptoms of gastroparesis of at least 12 weeks duration (does not have to be continuous) with varying degrees of nausea, vomiting, early satiety, and/or post-prandial fullness

⁃ an idiopathic etiology

⁃ abnormal gastric emptying scintigraphy (GES) results using a 4 hour low fat Egg Beaters® protocol within the last 6 months with either a gastric emptying rate \> 60% retention at 2 hours and/or \>10% retention at 4 hours.

∙ 4\) Stable medical treatment for Functional Dyspeptic or Gastroparesis during 1 month before study and during the study period.

∙ 5\) Avoidance of alcohol, nicotine, and caffeine for 24 hours prior to study session.

Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
Andrew Bolender, BA
abolender@mgh.harvard.edu
617-643-4297
Time Frame
Start Date: 2018-11-30
Estimated Completion Date: 2028-03-31
Participants
Target number of participants: 65
Treatments
Experimental: taVNS
Active or inactive taVNS
Authors
Brad Kuo, Vitaly Napadow
Related Therapeutic Areas
Sponsors
Leads: Massachusetts General Hospital

This content was sourced from clinicaltrials.gov